These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 38446351)

  • 21. Role of sacituzumab govitecan in solid tumors.
    Veeraballi S; Khawar Z; Aslam HM; Muzaffar M
    J Oncol Pharm Pract; 2022 Oct; 28(7):1617-1623. PubMed ID: 35404158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
    O'Shaughnessy J; Brufsky A; Rugo HS; Tolaney SM; Punie K; Sardesai S; Hamilton E; Loirat D; Traina T; Leon-Ferre R; Hurvitz SA; Kalinsky K; Bardia A; Henry S; Mayer I; Zhu Y; Phan S; Cortés J
    Breast Cancer Res Treat; 2022 Sep; 195(2):127-139. PubMed ID: 35545724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer.
    Manna M; Brabant M; Greene R; Chamberlain MD; Kumar A; Alimohamed N; Brezden-Masley C
    Curr Oncol; 2024 Sep; 31(9):5694-5708. PubMed ID: 39330050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
    Bardia A; Tolaney SM; Punie K; Loirat D; Oliveira M; Kalinsky K; Zelnak A; Aftimos P; Dalenc F; Sardesai S; Hamilton E; Sharma P; Recalde S; Gil EC; Traina T; O'Shaughnessy J; Cortes J; Tsai M; Vahdat L; Diéras V; Carey LA; Rugo HS; Goldenberg DM; Hong Q; Olivo M; Itri LM; Hurvitz SA
    Ann Oncol; 2021 Sep; 32(9):1148-1156. PubMed ID: 34116144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.
    Loriot Y; Kalebasty AR; Fléchon A; Jain RK; Gupta S; Bupathi M; Beuzeboc P; Palmbos P; Balar AV; Kyriakopoulos CE; Pouessel D; Sternberg CN; Tonelli J; Sierecki M; Zhou H; Grivas P; Barthélémy P; Bangs R; Tagawa ST
    Future Oncol; 2024; 20(23):1621-1631. PubMed ID: 38682560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sacituzumab Govitecan-hziy in Breast Cancer.
    Kwapisz D
    Am J Clin Oncol; 2022 Jul; 45(7):279-285. PubMed ID: 35728046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sacituzumab Govitecan: First Approval.
    Syed YY
    Drugs; 2020 Jul; 80(10):1019-1025. PubMed ID: 32529410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors.
    Starodub AN; Ocean AJ; Shah MA; Guarino MJ; Picozzi VJ; Vahdat LT; Thomas SS; Govindan SV; Maliakal PP; Wegener WA; Hamburger SA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2015 Sep; 21(17):3870-8. PubMed ID: 25944802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes.
    Rizzo A; Rinaldi L; Massafra R; Cusmai A; Guven DC; Forgia D; Latorre A; Giotta F
    Future Oncol; 2024; 20(20):1427-1434. PubMed ID: 38864297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
    Nie T; Blair HA
    Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
    Zeybek B; Manzano A; Bianchi A; Bonazzoli E; Bellone S; Buza N; Hui P; Lopez S; Perrone E; Manara P; Zammataro L; Altwerger G; Han C; Tymon-Rosario J; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin A
    Sci Rep; 2020 Jan; 10(1):973. PubMed ID: 31969666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.
    Mathew Thomas V; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Apr; 22(4):335-341. PubMed ID: 35249433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V; O'Shaughnessy J; Gray JE; Komiya T; Lang JM; Chang JC; Starodub A; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Wegener WA; Goswami T; Ocean AJ
    Ann Oncol; 2021 Jun; 32(6):746-756. PubMed ID: 33741442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
    Gray JE; Heist RS; Starodub AN; Camidge DR; Kio EA; Masters GA; Purcell WT; Guarino MJ; Misleh J; Schneider CJ; Schneider BJ; Ocean A; Johnson T; Gandhi L; Kalinsky K; Scheff R; Messersmith WA; Govindan SV; Maliakal PP; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM
    Clin Cancer Res; 2017 Oct; 23(19):5711-5719. PubMed ID: 28679770
    [No Abstract]   [Full Text] [Related]  

  • 38. Trastuzumab Deruxtecan: A Review in Gastric or Gastro-Oesophageal Junction Adenocarcinoma.
    Kang C
    Target Oncol; 2023 Nov; 18(6):981-989. PubMed ID: 37787931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors.
    Tagawa ST; Balar AV; Petrylak DP; Kalebasty AR; Loriot Y; Fléchon A; Jain RK; Agarwal N; Bupathi M; Barthelemy P; Beuzeboc P; Palmbos P; Kyriakopoulos CE; Pouessel D; Sternberg CN; Hong Q; Goswami T; Itri LM; Grivas P
    J Clin Oncol; 2021 Aug; 39(22):2474-2485. PubMed ID: 33929895
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.